NATHAN FOWLER to Receptors, Antigen, T-Cell
This is a "connection" page, showing publications NATHAN FOWLER has written about Receptors, Antigen, T-Cell.
Connection Strength
1.442
-
Comparative efficacy and safety of tisagenlecleucel and axicabtagene ciloleucel among adults with r/r follicular lymphoma. Leuk Lymphoma. 2024 Mar; 65(3):323-332.
Score: 0.587
-
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. Nat Med. 2022 02; 28(2):325-332.
Score: 0.509
-
Efficacy and safety of tisagenlecleucel in adult Japanese patients with relapsed or refractory follicular lymphoma: results from the phase 2 ELARA trial. Int J Hematol. 2023 Feb; 117(2):251-259.
Score: 0.136
-
Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas. Nat Med. 2020 12; 26(12):1878-1887.
Score: 0.117
-
Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update. Blood. 2024 04 25; 143(17):1713-1725.
Score: 0.037
-
Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma. Blood Adv. 2022 11 22; 6(22):5835-5843.
Score: 0.034
-
Breakthrough therapies in B-cell non-Hodgkin lymphoma. Ann Oncol. 2016 05; 27(5):778-87.
Score: 0.021